Tyra Biosciences (NASDAQ:TYRA) Trading 5.6% Higher – What’s Next?

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) shot up 5.6% during mid-day trading on Thursday . The stock traded as high as $22.75 and last traded at $23.2390. Approximately 207,790 shares traded hands during trading, a decline of 77% from the average daily volume of 898,715 shares. The stock had previously closed at $22.01.

Key Headlines Impacting Tyra Biosciences

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Initial SURF302 results support further development of dabogratinib in bladder cancer, providing evidence of potential activity for Tyra’s lead program. The Pharma Letter article
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $53 price target, signaling substantial potential upside if the clinical program succeeds. Benzinga analyst rating report
• Positive Sentiment: Director Rehan Verjee purchased 972 shares for approximately $20,004 at an average price of $20.58. The insider purchase may be viewed as a signal of confidence, although its size is modest relative to the company’s market value. SEC insider ownership filing
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, but the figures appear anomalous and provide little useful information about trading sentiment.
• Negative Sentiment: Coverage indicated that bladder-cancer response rates from SURF302 were below investor expectations, creating uncertainty about dabogratinib’s commercial and regulatory potential. BioSpace article
• Negative Sentiment: HC Wainwright lowered its price target from $45 to $30, although it retained a “Buy” rating, reflecting reduced near-term expectations following the trial update. Benzinga analyst rating report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of TYRA investors, adding a legal and reputational overhang. The announcement did not establish wrongdoing by Tyra. Pomerantz investor alert

Wall Street Analysts Forecast Growth

Several research firms recently commented on TYRA. HC Wainwright dropped their target price on Tyra Biosciences from $45.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday. Wolfe Research assumed coverage on Tyra Biosciences in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Jefferies Financial Group restated a “buy” rating and issued a $42.00 price target on shares of Tyra Biosciences in a report on Wednesday, August 5th. Bank of America upped their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Finally, JonesTrading assumed coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective on the stock. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.88.

Tyra Biosciences Stock Performance

The stock’s fifty day simple moving average is $28.39 and its two-hundred day simple moving average is $31.84. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -9.18 and a beta of 0.73.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Analysts predict that Tyra Biosciences, Inc. will post -2.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Tidal Investments LLC acquired a new stake in Tyra Biosciences during the second quarter worth about $943,000. WINTON GROUP Ltd acquired a new position in shares of Tyra Biosciences in the 2nd quarter valued at about $537,000. Engineers Gate Manager LP acquired a new position in shares of Tyra Biosciences in the 2nd quarter valued at about $1,021,000. Squarepoint Ops LLC grew its holdings in shares of Tyra Biosciences by 211.3% during the 2nd quarter. Squarepoint Ops LLC now owns 63,805 shares of the company’s stock worth $2,038,000 after purchasing an additional 43,311 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of Tyra Biosciences by 55,815.5% during the 2nd quarter. California State Teachers Retirement System now owns 783,935 shares of the company’s stock worth $24,544,000 after purchasing an additional 782,533 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.